查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984153

脑部疾病诊断方式及软体市场：依软体类型、影像方式、疾病适应症、部署方法、通路及最终用户划分－2026-2032年全球市场预测

Brain Disease Modalities & Software Market by Software Type, Imaging Modality, Disease Indication, Deployment Mode, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，脑疾病诊断和软体市场价值将达到 152.8 亿美元，到 2026 年将成长到 162.7 亿美元，到 2032 年将达到 244.4 亿美元，复合年增长率为 6.93%。

主要市场统计数据
基准年 2025 152.8亿美元
预计年份：2026年 162.7亿美元
预测年份 2032 244.4亿美元
复合年增长率 (%) 6.93%

全面概述了诊断影像技术、智慧软体和临床需求的创新如何交会融合，从而重塑脑部疾病的诊断和治疗。

先进影像技术、智慧软体和不断发展的临床路径的融合正在重塑我们检测、监测和管理脑部疾病的方式。本执行摘要整合了影响神经系统疾病诊断和决策生态系统的关键变革驱动因素，并将技术创新与不断变化的临床需求和监管要求联繫起来。医疗设备製造商、软体开发商、临床网路和研究机构等相关人员正在寻求一个互通性、数据可靠性和演算法透明度与诊断灵敏度同等重要的环境。

多模态成像、演算法智慧和分散式医疗服务技术的整合如何重新定义临床价值和竞争差异化。

随着计算方法的成熟、影像能力的多元化以及医疗服务分散化，脑部疾病诊断和软体领域正经历着变革性的转变。在所有显像模式下，高解析度采集、多模态融合和先进的后处理的结合，使得以往在常规工作流程中难以检测到的生物标记得以测量。携带式平台和讯号处理技术的改进正在重塑电诊断和功能测试技术，而混合成像方法则能够对神经退化性疾病和急性神经系统疾病进行更精确的表型分析。

本分析探讨了 2025 年的价格调整如何重塑整个神经诊断硬体和软体生态系统的筹资策略、供应链韧性和部署选择。

2025年关税政策的变化为神经技术领域的全球供应链、筹资策略和跨境服务交付带来了新的考量。针对特定类型医疗设备和软体相关硬体组件的关税促使製造商和经销商重新评估筹资策略，他们正在考虑近岸外包、组件替代和合约保障措施，以降低成本波动风险。分阶段实施的关税不仅影响资本设备，也影响相关的服务模式，因为它们会影响本地部署设备和云端服务的部署选择。

将影像方式、软体类型、疾病适应症、最终用户环境、部署模型和通路联繫起来的详细观点有助于制定产品策略。

了解市场区隔对于确定产品开发优先顺序、优化商业化策略以及使临床检验工作与最终用户需求保持一致至关重要。在影像学领域，诊断路径包括电脑断层扫描（CT）（包括常规CT和频谱CT）；脑电图（EEG）（分为携带式和常规EEG）；扩散张量成像（DTI）；磁振造影（MRI）（包括功能性磁振造影（fMRI ）和结构磁振造影（sMRI））；脑磁图（MEG）（分为诱发电位和静息态MEG）；正子断层扫描（PET）（包括淀粉样蛋白和FDG示踪剂）；以及从高解析度成像到经颅都卜勒超音波的超音波方法。每种成像方式都有其独特的资料特征、临床工作流程和整合挑战，这些都会影响软体的设计和部署。

受监管、基础设施和支付方多样性的驱动，美洲、欧洲、中东和非洲以及亚太地区的区域趋势正在影响技术的采用和商业化。

区域趋势持续对技术采纳路径、监管预期和伙伴关係模式产生重大影响。在美洲，以商业为导向的报销框架备受重视，这有助于快速实用化和早期采用检验的诊断方法，尤其是在先进的医院系统和专科诊所。该地区强大的研究基础设施也支持合作进行的临床和多中心检验研究，这些研究成果通常用于更广泛的监管申报和商业化宣传活动。

面向神经诊断和软体供应商的策略行动和伙伴关係模式，旨在推动技术差异化、临床检验和可扩展的商业化

在脑疾病诊断和软体领域，主要企业正透过互补策略实现差异化竞争，这些策略融合了技术创新、临床证据的生成以及伙伴关係生态系统。许多成熟的医疗设备製造商正在扩展其成像平台，为其嵌入式分析功能并增强连接性；而专业的软体公司则专注于扩充性的人工智慧流程和云端原生服务，并将互通性和合规性放在首位。新兴技术供应商，即从学术研究领域衍生而来的企业，正凭藉新型生物标誌物、讯号处理技术的进步以及旨在加速临床工作流程的改进型使用者介面展开竞争。

为供应商提供切实可行的策略重点和实施程序，以加快部署速度，确保合规性，并在各种医疗保健环境中提供可衡量的临床价值。

在不断变化的环境中，寻求创造价值的领导者必须协调其在技术、临床检验、监管准备和商业性执行方面的策略。首先，他们必须优先考虑产品设计的互通性和模组化，以促进产品与各种医院和诊所基础设施的集成，从而实现快速部署并降低最终用户的整体拥有成本。同时，他们必须投资于清晰的演算法管治框架，以支持可解释性、减少偏差和生命週期管理，从而满足日益严格的监管要求并增强临床医生的信心。

结合专家访谈、第二手资料整合和检验等稳健的混合方法研究途径，为实用可靠的研究结果奠定了基础。

本报告的分析是基于一种综合调查方法，该方法结合了初步研究、严谨的二手资讯分析和方法论三角验证，以确保分析的可靠性。初步研究包括对临床负责人、技术架构师、采购专家和监管顾问进行结构化访谈，以获取关于技术采纳驱动因素、实施挑战和证据要求的第一手观点。这些专家的意见提供了关于临床工作流程、资料互通性限制以及对实际性能预期等方面的细緻背景资讯。

此总结重点阐述了技术成熟度、临床证据和适应性商业化如何决定长期临床影响和采用轨迹。

一项整合了技术趋势、监管变化和区域发展的分析表明，未来诊断准确性和临床决策支援将与营运适应性和可验证的临床价值日益紧密地交织在一起。影像技术和演算法系统正从概念验证阶段迈向能够影响临床路径的实用化工具，前提是它们必须具备严格的检验、可解释的性能特征以及考虑区域限制的部署模型。不断变化的收费政策、法规和支付方期望的累积影响凸显了製定稳健的商业策略和高度适应性的产品架构的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 脑疾病诊断方式及软体市场：依软体类型划分

  • 基于人工智慧的软体
    • 深度学习演算法
    • 机器学习演算法
  • 临床决策支援软体
  • 诊断软体
    • 影像分析软体
    • 分割软体
  • 监控软体
    • 神经生理监测
    • 远端患者监护
  • 远端医疗平台
  • 工作流程管理软体

第九章 依影像方法分類的脑部疾病诊断模式与软体市场

  • 电脑断层扫描
    • 常规CT
    • 频谱CT
  • 脑电图（EEG）
    • 携带式脑电图（EEG）
    • 常规脑电图
  • 磁振造影
    • 扩散张量造影
    • 功能性磁振造影
    • 结构磁振造影
  • 脑磁图
    • 诱发反应
    • 静止状态
  • 正子断层扫描
    • 淀粉样蛋白PET
    • FDG-PET
  • 超音波
    • 高解析度
    • 经颅都卜勒

第十章：脑部疾病诊断方式及软体市场：依疾病适应症划分

  • 阿兹海默症
  • 癫痫
    • 局部癫痫发作
    • 整体癫痫发作
  • 多发性硬化症
  • 帕金森氏症
  • 中风
    • 出血性中风
    • 缺血性中风
  • 创伤性脑损伤
    • 轻度脑外伤
    • 严重创伤性脑损伤

第十一章 脑疾病诊断方式及软体市场：依部署模式划分

  • 基于云端的
  • 杂交种
  • 现场

第十二章 脑疾病诊断方式及软体市场：依通路划分

  • 直销
  • 销售代理
  • 线上平台

第十三章 脑疾病诊断方式与软体市场：依最终使用者划分

  • 门诊手术中心
  • 诊所
    • 神经科诊所
    • 復健诊所
  • 诊断影像中心
  • 医院
    • 私立医院
    • 公立医院
  • 研究机构

第十四章 脑疾病诊断方式与软体市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：脑疾病诊断方式与软体市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 脑疾病诊断方式与软体市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国脑疾病诊断方式与软体市场

第十八章：中国脑疾病诊断方式及软体市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aspect Imaging Ltd.
  • Brainomix Limited
  • Canon Medical Systems Corporation
  • Carestream Health, Inc.
  • Esaote SpA
  • Fujifilm Holdings Corporation
  • General Electric Company,
  • Imaging Biometrics LLC
  • International Business Machines Corporation
  • IXICO plc.
  • Koninklijke Philips NV,
  • MIM Software, Inc.
  • Quantib BV
  • ScienceSoft USA Corporation
  • Siemens Healthineers AG
  • VUNO Inc.
Product Code: MRR-5C6F41F5AF8F

The Brain Disease Modalities & Software Market was valued at USD 15.28 billion in 2025 and is projected to grow to USD 16.27 billion in 2026, with a CAGR of 6.93%, reaching USD 24.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.28 billion
Estimated Year [2026] USD 16.27 billion
Forecast Year [2032] USD 24.44 billion
CAGR (%) 6.93%

Comprehensive orientation to the intersection of imaging innovation, intelligent software, and clinical imperatives reshaping diagnosis and management of brain disorders

The convergence of advanced imaging modalities, intelligent software, and evolving clinical pathways is reshaping how brain diseases are detected, monitored, and managed. This executive summary synthesizes the critical vectors of change affecting diagnostic and decision-support ecosystems for neurological conditions, integrating technological innovation with shifting clinical needs and regulatory scrutiny. Stakeholders across device manufacturers, software developers, clinical networks, and research institutions are navigating an environment where interoperability, data fidelity, and algorithmic transparency are as consequential as diagnostic sensitivity.

Clinical demand is increasingly focused on tools that deliver actionable insights at the point of care and that scale across diverse care settings. Simultaneously, the proliferation of artificial intelligence and deep learning architectures has introduced new performance thresholds and design imperatives for software intended to support clinicians. As a result, organizations must reconcile the promise of higher diagnostic confidence with the operational realities of deployment, data governance, and long-term clinical validation.

This introduction frames the subsequent analysis by outlining the technological building blocks, the stakeholder dynamics that drive adoption, and the regulatory and reimbursement contexts that now exert significant influence over product roadmaps. The aim is to provide a clear analytic lens for executives seeking to align investment decisions with clinical value, implementation feasibility, and sustainable competitive positioning.

How converging advances in multimodal imaging, algorithmic intelligence, and decentralized care delivery are redefining clinical value and competitive differentiation

The landscape for brain disease diagnostics and software is undergoing transformative shifts as computational methods mature, imaging capabilities diversify, and care delivery decentralizes. Across imaging modalities, the combination of higher-resolution acquisition, multimodal fusion, and advanced post-processing has made previously latent biomarkers measurable in routine workflows. Electrodiagnostic and functional techniques are being reimagined through ambulatory platforms and improved signal processing, while hybrid imaging approaches enable more precise phenotyping of neurodegenerative and acute neurological conditions.

Software advances have been equally disruptive. The integration of deep learning and machine learning techniques into clinical decision support and diagnostic software has expanded the scope of automated interpretation, lesion detection, and prognosis modeling. These algorithmic systems are increasingly validated against multi-institutional datasets and are moving toward regulatory acceptance frameworks that demand explainability and reproducibility. Workflow management and telehealth platforms are bridging gaps between imaging centers, clinics, and tertiary care hospitals, enabling remote interpretation, real-time monitoring, and collaborative care models.

Concurrently, other structural forces are accelerating change: tighter regulatory scrutiny around AI-based medical devices, the emergence of cloud and hybrid deployment architectures, and the demand for standardized data exchange are all reshaping product architectures. As providers seek to optimize patient throughput and clinicians demand more intuitive interfaces, vendors must prioritize modular solutions that align with diverse end-user environments while maintaining robust data governance. Taken together, these shifts are redefining competitive differentiation from siloed product features toward ecosystem interoperability and sustained clinical evidence generation.

Analyzing how 2025 tariff adjustments reshaped procurement strategies, supply chain resilience, and deployment choices across neurodiagnostic hardware and software ecosystems

Tariff policy changes in 2025 introduced new considerations for global supply chains, procurement strategies, and cross-border service delivery within the neurotechnology landscape. Tariffs aimed at certain classes of medical equipment and software-related hardware components have driven a reassessment of sourcing strategies, with manufacturers and distributors examining nearshoring, component substitution, and contractual safeguards to mitigate cost volatility. The impact extends beyond capital equipment to associated service models, as tiered duties influence deployment choices between on-premise appliances and cloud-enabled services.

In response, organizations have accelerated supply chain segmentation to preserve critical capabilities while limiting exposure to tariff-driven price shifts. Contract renegotiations, more conservative inventory strategies, and selective supplier diversification have become commonplace as vendor and provider organizations seek to maintain continuity of clinical services. For software providers that bundle hardware-dependent solutions, tariffs have prompted a re-evaluation of licensing structures and greater emphasis on subscription and cloud-native models that decouple end-user costs from hardware procurement cycles.

Moreover, tariff-induced pressures have highlighted the value of adaptable deployment modes, including hybrid solutions that allow sensitive data processing to occur locally while leveraging cloud services for non-sensitive analytics and updates. For health systems operating across jurisdictions, tariff considerations are now embedded in procurement frameworks alongside clinical performance criteria and regulatory compliance. Looking ahead, resilience planning that incorporates trade policy scenarios will be essential for sustaining product rollouts and preserving margins in a landscape where geopolitical and economic levers can rapidly alter cost equations.

Deep segmentation perspective that connects imaging modalities, software types, disease indications, end-user environments, deployment modes, and distribution pathways to inform product strategy

Understanding segmentation is essential for framing product development priorities, tailoring commercialization approaches, and aligning clinical validation efforts with end-user needs. In imaging modalities, diagnostic pathways encompass computed tomography with its conventional and spectral variants, electroencephalography differentiated into ambulatory and routine formats, magnetic resonance imaging that includes diffusion tensor imaging, functional MRI, and structural MRI, magnetoencephalography split into evoked response and resting-state methods, positron emission tomography characterized by amyloid and FDG tracers, and ultrasound approaches ranging from high-resolution imaging to transcranial Doppler assessments. Each modality presents distinct data characteristics, clinical workflows, and integration challenges that influence software design and deployment.

On the software side, segmentation spans AI-based solutions that leverage deep learning and machine learning algorithms, clinical decision support platforms, diagnostic software such as image analysis and segmentation tools, monitoring software divided into neurophysiological monitoring and remote patient monitoring, telehealth platforms, and workflow management solutions. The technical architecture and validation pathways differ markedly between algorithmic components intended for autonomous interpretation and software that augments clinician decision-making, demanding tailored evidence dossiers and interoperability standards.

Disease indication segmentation covers a spectrum of neurological disorders including Alzheimer's disease, epilepsy with focal onset and generalized onset subtypes, multiple sclerosis, Parkinson's disease, stroke encompassing hemorrhagic and ischemic presentations, and traumatic brain injury with mild and severe classifications. Patient pathways, biomarker relevance, and the balance between acute versus longitudinal monitoring shape diagnostic priorities across these indications. End-user segmentation stretches across ambulatory surgical centers, clinics with neurology and rehabilitation subtypes, diagnostic imaging centers, hospitals with private and public distinctions, and research institutes engaged in translational science. Deployment modes include cloud-based, hybrid, and on-premise architectures, each presenting different trade-offs in latency, data sovereignty, and maintenance overhead. Distribution channels run from direct sales to distributors and online platforms, influencing go-to-market cadence, after-sales support models, and partner enablement strategies. Integrating these layers of segmentation is critical for designing product roadmaps that respond to clinical workflows, regulatory requirements, and the commercial dynamics of diverse healthcare settings.

Regional dynamics shaping adoption and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific driven by regulation, infrastructure, and payer diversity

Regional dynamics continue to exert a pronounced influence on adoption pathways, regulatory expectations, and partnership models. In the Americas, healthcare delivery structures emphasize rapid translation of validated diagnostics and commercially oriented reimbursement frameworks that facilitate early adoption, particularly within advanced hospital systems and specialist clinics. The region's sizable research infrastructure also supports clinical collaborations and multicenter validation studies that are frequently leveraged for broader regulatory submissions and commercialization campaigns.

Europe, the Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with significant national-level variation. European regulatory rigor and data protection norms have incentivized vendors to prioritize algorithmic transparency and robust clinical evidence, while markets in the Middle East and Africa exhibit opportunities for leapfrogging to cloud-enabled services in contexts where centralized imaging infrastructure is limited. Accessibility, cost-containment pressures, and diverse payer models necessitate adaptable pricing strategies and flexible deployment options to achieve broader adoption across this expansive region.

The Asia-Pacific region is characterized by rapid infrastructure expansion, strong government-led investments in healthcare modernization, and vibrant local innovation ecosystems. Diverse payer structures and varying levels of clinical specialization drive a dual approach from vendors: offering scalable cloud-based solutions for urban centers with advanced digital infrastructure while providing resilient on-premise or hybrid systems for facilities with constrained connectivity. Collaboration with regional research institutes and localization of validation studies often underpin successful market entry and uptake across Asia-Pacific markets.

Strategic company behaviors and partnership models driving technological differentiation, clinical validation, and scalable commercialization across neurodiagnostic and software vendors

Key companies operating within the brain disease modalities and software space are differentiating through complementary strategies that combine technological innovation, clinical evidence generation, and partnership ecosystems. Many established medical device manufacturers are augmenting imaging platforms with embedded analytics and enhanced connectivity, while specialized software firms focus on scalable AI pipelines and cloud-native services that prioritize interoperability and regulatory readiness. Emerging technology providers, frequently spun out from academic research, are competing on novel biomarkers, signal processing advances, or improved user interfaces designed to accelerate clinical workflows.

Strategic collaborations and licensing agreements between hardware vendors and software developers have become central to accelerating time-to-clinic and expanding distribution reach. Additionally, partnerships with clinical networks and research institutes are increasingly used to secure real-world validation and to navigate complex reimbursement pathways. Companies are also investing in post-market surveillance and continuous learning systems to ensure algorithmic performance remains robust across diverse patient populations and imaging platforms.

Operationally, successful organizations emphasize modular product architectures that can be deployed on-premise, in hybrid configurations, or via cloud services, thereby accommodating the heterogeneous needs of hospitals, clinics, and diagnostic centers. Commercial excellence is underpinned by comprehensive support models, professional services for implementation, and training programs that reduce clinician friction during adoption. Collectively, these strategic choices reflect an industry that is balancing innovation with pragmatic approaches to scale, compliance, and clinical acceptance.

Practical strategic priorities and implementation steps for vendors to accelerate adoption, ensure compliance, and deliver measurable clinical value across diverse care settings

Leaders seeking to capture value in this evolving landscape should align their strategies across technology, clinical validation, regulatory preparedness, and commercial execution. First, prioritize interoperability and modularity in product design to facilitate integration into heterogeneous hospital and clinic infrastructures, enabling faster deployments and lower total cost of ownership for end users. Concurrently, invest in clear algorithmic governance frameworks that support explainability, bias mitigation, and lifecycle management to meet increasingly stringent regulatory expectations and to build clinician trust.

Second, embed clinical evidence generation into commercialization roadmaps by forging early partnerships with treatment centers and research institutes to produce reproducible, peer-reviewed outcomes. These collaborations should extend beyond retrospective validation into prospective, real-world studies that demonstrate clinical utility and workflow efficiency. Third, adopt flexible deployment strategies that permit cloud, hybrid, and on-premise configurations to address data sovereignty, latency, and connectivity constraints; this flexibility will be crucial when navigating tariff-driven procurement dynamics or region-specific infrastructure limitations.

Fourth, refine go-to-market approaches by tailoring distribution and pricing models to end-user segmentation. Direct engagement is often essential for large hospitals and health systems, whereas distributors and online channels can accelerate penetration within diagnostic centers and ambulatory networks. Finally, build a robust post-deployment support ecosystem that includes training, maintenance, and outcome-tracking services to sustain utilization, gather post-market data, and create defensible competitive advantage over time. Executing on these recommendations will require cross-functional alignment and an emphasis on measurable clinical outcomes as the primary metric of success.

Robust mixed-methods research approach combining primary expert engagements, secondary evidence synthesis, and triangulated validation to underpin practical, trustworthy insights

The analysis underpinning this report draws on an integrated research methodology that combines primary engagements, rigorous secondary intelligence, and methodological triangulation to ensure analytical robustness. Primary research included structured interviews with clinical leaders, technical architects, procurement specialists, and regulatory advisors to capture firsthand perspectives on adoption drivers, implementation challenges, and evidence requirements. These expert inputs offered nuanced context on clinical workflows, data interoperability constraints, and real-world performance expectations.

Secondary research synthesized peer-reviewed literature, technology whitepapers, regulatory guidance documents, and clinical practice recommendations to establish a foundation of domain knowledge and to validate technical assertions. Where applicable, public clinical registries and standards bodies' publications were referenced to ensure alignment with prevailing clinical and technical norms. Qualitative insights were complemented by structured comparative assessments of technology features, deployment modes, and validation practices to articulate relative strengths and limitations across solution classes.

Data integrity was maintained through methodological triangulation, cross-checking stakeholder testimonies against published evidence and regulatory documents. The research process emphasized transparency in assumption-setting, careful delineation of data sources, and the use of consensus approaches when reconciling divergent expert views. Ethical considerations and data privacy compliance were observed throughout primary data collection, and findings were synthesized to support practical decision-making for industry leaders and healthcare providers.

Concluding synthesis highlighting how technology maturity, clinical evidence, and adaptive commercialization will determine long-term clinical impact and adoption trajectories

The synthesis of technological trends, regulatory shifts, and regional dynamics points to a future in which diagnostic precision and clinical decision support are increasingly interwoven with operational adaptability and demonstrable clinical value. Imaging modalities and algorithmic systems are moving beyond proof-of-concept to operationalized tools that can influence care pathways, provided they are accompanied by rigorous validation, explainable performance characteristics, and deployment models attuned to local constraints. The cumulative effects of tariff policies, regulatory evolution, and payer expectations underscore the need for resilient commercial strategies and adaptable product architectures.

For healthcare providers, the imperative is to adopt solutions that integrate seamlessly with existing workflows while offering tangible improvements in diagnostic confidence and efficiency. For vendors, success will hinge on balancing innovation with disciplined clinical evidence generation, interoperability commitments, and comprehensive support structures that facilitate adoption across varied end-user environments. Ultimately, the interplay of technology, evidence, and execution will determine which solutions achieve sustainable clinical impact and market acceptance. Stakeholders who proactively address these dimensions will be best positioned to advance patient outcomes and to realize long-term strategic objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Disease Modalities & Software Market, by Software Type

  • 8.1. Ai Based Software
    • 8.1.1. Deep Learning Algorithms
    • 8.1.2. Machine Learning Algorithms
  • 8.2. Clinical Decision Support Software
  • 8.3. Diagnostic Software
    • 8.3.1. Image Analysis Software
    • 8.3.2. Segmentation Software
  • 8.4. Monitoring Software
    • 8.4.1. Neurophysiological Monitoring
    • 8.4.2. Remote Patient Monitoring
  • 8.5. Telehealth Platform
  • 8.6. Workflow Management Software

9. Brain Disease Modalities & Software Market, by Imaging Modality

  • 9.1. Computed Tomography
    • 9.1.1. Conventional Ct
    • 9.1.2. Spectral Ct
  • 9.2. Electroencephalography
    • 9.2.1. Ambulatory Eeg
    • 9.2.2. Routine Eeg
  • 9.3. Magnetic Resonance Imaging
    • 9.3.1. Diffusion Tensor Imaging
    • 9.3.2. Functional Mri
    • 9.3.3. Structural Mri
  • 9.4. Magnetoencephalography
    • 9.4.1. Evoked Response
    • 9.4.2. Resting State
  • 9.5. Positron Emission Tomography
    • 9.5.1. Amyloid Pet
    • 9.5.2. Fdg Pet
  • 9.6. Ultrasound
    • 9.6.1. High Resolution
    • 9.6.2. Transcranial Doppler

10. Brain Disease Modalities & Software Market, by Disease Indication

  • 10.1. Alzheimer's Disease
  • 10.2. Epilepsy
    • 10.2.1. Focal Onset
    • 10.2.2. Generalized Onset
  • 10.3. Multiple Sclerosis
  • 10.4. Parkinson's Disease
  • 10.5. Stroke
    • 10.5.1. Hemorrhagic Stroke
    • 10.5.2. Ischemic Stroke
  • 10.6. Traumatic Brain Injury
    • 10.6.1. Mild Tbi
    • 10.6.2. Severe Tbi

11. Brain Disease Modalities & Software Market, by Deployment Mode

  • 11.1. Cloud Based
  • 11.2. Hybrid
  • 11.3. On Premise

12. Brain Disease Modalities & Software Market, by Distribution Channel

  • 12.1. Direct
  • 12.2. Distributors
  • 12.3. Online Platforms

13. Brain Disease Modalities & Software Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Clinics
    • 13.2.1. Neurology Clinics
    • 13.2.2. Rehabilitation Clinics
  • 13.3. Diagnostic Imaging Centers
  • 13.4. Hospitals
    • 13.4.1. Private Hospitals
    • 13.4.2. Public Hospitals
  • 13.5. Research Institutes

14. Brain Disease Modalities & Software Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Disease Modalities & Software Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Disease Modalities & Software Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Brain Disease Modalities & Software Market

18. China Brain Disease Modalities & Software Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aspect Imaging Ltd.
  • 19.6. Brainomix Limited
  • 19.7. Canon Medical Systems Corporation
  • 19.8. Carestream Health, Inc.
  • 19.9. Esaote S.p.A.
  • 19.10. Fujifilm Holdings Corporation
  • 19.11. General Electric Company,
  • 19.12. Imaging Biometrics LLC
  • 19.13. International Business Machines Corporation
  • 19.14. IXICO plc.
  • 19.15. Koninklijke Philips N.V.,
  • 19.16. MIM Software, Inc.
  • 19.17. Quantib B.V.
  • 19.18. ScienceSoft USA Corporation
  • 19.19. Siemens Healthineers AG
  • 19.20. VUNO Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEEP LEARNING ALGORITHMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MACHINE LEARNING ALGORITHMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICAL DECISION SUPPORT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEGMENTATION SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROPHYSIOLOGICAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REMOTE PATIENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TELEHEALTH PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY WORKFLOW MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CONVENTIONAL CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SPECTRAL CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY EEG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ROUTINE EEG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STRUCTURAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EVOKED RESPONSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESTING STATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMYLOID PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FDG PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HIGH RESOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRANSCRANIAL DOPPLER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY FOCAL ONSET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY GENERALIZED ONSET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HEMORRHAGIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MILD TBI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MILD TBI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MILD TBI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEVERE TBI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEVERE TBI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SEVERE TBI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REHABILITATION CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REHABILITATION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REHABILITATION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY EPILEPSY, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY STROKE, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DEPLOYMENT MODE, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY AI BASED SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY DIAGNOSTIC SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MONITORING SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY IMAGING MODALITY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY MAGNETOENCEPHALOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRAIN DISEASE MODALITIES & SOFTWARE MARKET SIZE, BY POSITRON EMISSION TOM